Skip to content

Diagnosis and objective testing

TL;DR — Asthma is not established by symptoms alone: diagnosis requires a compatible pattern plus objective evidence of variable expiratory airflow limitation, airway hyperresponsiveness, or a reproducible anti-inflammatory response. Spirometry with bronchodilator testing is the first test, but a normal result between episodes is common enough that repeat testing, peak-flow monitoring, or bronchial challenge may be needed (Brigham 2015, PMID 26335833). In a Canadian reassessment cohort, current asthma was excluded in 33.1% of 613 adults carrying a physician diagnosis, showing why confirmation before indefinite treatment matters (Aaron 2017, PMID 28114551). FeNO identifies type-2 airway inflammation and corticosteroid responsiveness rather than asthma itself; low FeNO cannot exclude non-type-2 asthma (Loewenthal 2022, PMID 35253144). No single test is a gold standard, so discordant results should trigger repetition under symptomatic conditions and structured consideration of mimics rather than automatic escalation.

What the diagnosis must demonstrate

Asthma diagnosis has two separable components:

  1. a history of variable wheeze, breathlessness, chest tightness and/or cough; and
  2. objective variability in expiratory airflow or airway responsiveness in a clinically compatible setting (Rothe 2018, PMID 29614508; Brigham 2015, PMID 26335833).

Symptoms alone are sensitive but nonspecific. Wheeze can arise from inducible laryngeal obstruction, fixed central-airway lesions, COPD, heart failure or bronchiectasis; cough can reflect upper-airway disease, reflux, eosinophilic bronchitis or medication; exertional breathlessness can reflect deconditioning, obesity, dysfunctional breathing or cardiac disease (Armeftis 2023, PMID 37358228; Aaron 2018, PMID 29756989).

Objective variability is also not uniquely asthmatic. Bronchodilator responsiveness and methacholine hyperresponsiveness occur in other airway diseases, so a positive result modifies probability; it does not replace clinical interpretation (Brigham 2015, PMID 26335833; Cockcroft 2020, PMID 32768054).

Practical sequence

Step Test or action Positive evidence Main limitation
1 Record symptom pattern, triggers, smoking/vaping, medication and occupational timing Recurrent variability; nocturnal/early-morning symptoms; exercise, allergen, viral or work association Pattern is not specific (Armeftis 2023, PMID 37358228)
2 Pre/post-bronchodilator spirometry Obstruction plus significant FEV1 improvement supports variable airflow limitation Normal spirometry between attacks does not exclude asthma (Brigham 2015, PMID 26335833)
3 Repeat spirometry when symptomatic or after withholding bronchodilator when safe Between-visit or within-episode variability Treatment can suppress the signal (Malinovschi 2025, PMID 40371566)
4 Serial peak expiratory flow (PEF) Diurnal or exposure-linked variability Effort, meter, recording and charting quality matter (Brigham 2015, PMID 26335833)
5 Bronchial challenge Methacholine, mannitol or exercise response demonstrates hyperresponsiveness Direct challenge is sensitive but incompletely specific (Cockcroft 2020, PMID 32768054)
6 FeNO and blood eosinophils Supports type-2 inflammation and probable ICS responsiveness Atopy, smoking, infection and current ICS alter values; not a stand-alone diagnosis (Loewenthal 2022, PMID 35253144)
7 Targeted alternative testing Flow-volume loop, laryngoscopy, imaging, diffusion capacity, cardiac or infection work-up Choose from the discordance; avoid indiscriminate panels (Aaron 2018, PMID 29756989)

Treatment should not be withheld in an emergency to obtain pristine diagnostic data. Outside acute care, however, objective confirmation is easiest before long-term ICS suppresses variability and type-2 biomarkers (Armeftis 2023, PMID 37358228).

Spirometry

Core measures are FEV1, FVC and FEV1/FVC. The ratio should be interpreted against age-appropriate lower limits of normal rather than a fixed threshold alone; low FEV1/FVC demonstrates airflow obstruction, while FEV1 quantifies impairment (Tepper 2012, PMID 22386510).

A commonly used adult bronchodilator criterion is an increase in FEV1 of both at least 12% and at least 200 mL after bronchodilator, but failure to cross this threshold on one visit does not exclude asthma (Urso 2012, PMID 22825384; Boparai 2024, PMID 38151386). Variability can be episodic, and controller therapy, recent bronchodilator, technique and lack of current symptoms all reduce sensitivity.

Between-visit FEV1 variability has diagnostic information but is too insensitive to stand alone. In adults evaluated for asthma, diagnostic performance depended strongly on the variability threshold and testing interval (Dean 2018, PMID 29877740).

Spirometric quality is part of the diagnostic test: inadequate inspiration, early termination, cough and inconsistent effort can mimic restriction or hide obstruction. A technically unacceptable trace should be repeated rather than interpreted as biology (Tepper 2012, PMID 22386510).

Peak-flow monitoring

Serial PEF is useful when office spirometry is normal or unavailable and when exposure-linked variability is the question. A structured diary should use the same meter, record best-of-three efforts at consistent times, document symptoms and reliever use, and include work and non-work days when occupational asthma is possible (Jolly 2015, PMID 26461873).

PEF has lower information content and greater effort dependence than spirometry. Unsupervised logs can contain technique drift, transcription artifacts and selective measurement; digital meters reduce transcription error but do not make the maneuver effort-independent.

For work-related asthma, serial PEF across working and non-working periods is moderately recommended, while early spirometry and exposure history remain essential (Jolly 2015, PMID 26461873). Specific inhalation challenge is a specialist reference procedure for selected occupational agents, not a routine primary-care test (Tarlo 2003, PMID 12704344).

Bronchial challenge

Direct methacholine challenge tests airway smooth-muscle responsiveness. It is most useful when symptoms suggest asthma but baseline spirometry and bronchodilator testing are nondiagnostic (Cockcroft 2020, PMID 32768054).

Challenge Signal Best use Important caveat
Methacholine Concentration/dose producing a specified FEV1 fall Excluding current asthma when pre-test probability is intermediate A positive result is not specific; medications and protocol affect response (Cockcroft 2020, PMID 32768054)
Mannitol Indirect osmotic airway response Demonstrating active hyperresponsiveness, often closer to inflammatory activity Generally less sensitive than methacholine; availability varies
Exercise/eucapnic hyperventilation Post-exercise FEV1 fall Exercise-induced bronchoconstriction, athletes or exertional symptoms Environmental conditions and exercise intensity must be standardized
Specific occupational challenge Response to a suspected workplace agent Complex occupational attribution Specialist setting, exposure and safety controls required (Tarlo 2003, PMID 12704344)

A negative methacholine test under appropriate conditions makes active asthma less likely, but false negatives occur after ICS treatment, during low-exposure periods, with protocol differences, or when exercise-specific disease is the phenotype (Cockcroft 2020, PMID 32768054; Selvanathan 2020, PMID 32298731).

FeNO: inflammation, not obstruction

FeNO arises largely from inducible nitric oxide synthase in airway epithelium under IL-4/IL-13 signaling. It is therefore a noninvasive marker of type-2 airway inflammation, not a direct measure of airflow limitation (Escamilla-Gil 2022, PMID 35547356).

ATS interpretation uses contextual bands rather than a universal asthma cutoff; high FeNO supports eosinophilic inflammation and likely corticosteroid responsiveness, while intermediate values require clinical interpretation (Dweik 2011, PMID 21885636). Guideline cutoffs differ, which itself limits interchangeability (Loewenthal 2022, PMID 35253144).

FeNO is increased by allergic/type-2 biology and can be reduced by ICS adherence, smoking and some biologics. Suppression during directly observed ICS can expose previously unrecognized nonadherence in difficult asthma (Butler 2021, PMID 33369570).

The test is most useful as part of a bundle:

  • compatible symptoms plus variable airflow establishes the airway-disease diagnosis;
  • FeNO and eosinophils characterize inflammatory risk;
  • repeated biomarker measurement is more informative than assuming a stable endotype (Loewenthal 2022, PMID 35253144).

Children and preschool disease

For children aged 5–16 years, ERS recommends spirometry, bronchodilator reversibility and FeNO as first-line tests and recommends against diagnosis from history alone or from a single abnormal objective test (Gaillard 2021, PMID 33863747).

Preschool diagnosis is harder because episodic viral wheeze is common and conventional spirometry may not be feasible. With trained personnel, spirometry is often possible from about age five, oscillometry and plethysmography from around age three, and FeNO from around age five; published preschool thresholds remain less standardized than school-age spirometry (Chawes 2022, PMID 35197431).

Objective-test reviews in children find no single test sufficiently accurate across all settings. Sequential testing and follow-up are therefore part of the diagnosis rather than evidence of failure (Danvers 2020, PMID 30954449).

Overdiagnosis and underdiagnosis

The errors coexist because access to testing and case selection differ.

Problem Quantitative anchor Consequence
Previously diagnosed adults without confirmable current asthma 203/613 (33.1%) had current asthma excluded after serial spirometry, challenge and medication taper in a Canadian prospective cohort (Aaron 2017, PMID 28114551) Unnecessary long-term treatment and missed alternative diagnosis
Obesity and symptom attribution Objective reassessment excluded asthma in substantial proportions of both obese and non-obese adults (Aaron 2008, PMID 19015563) Dyspnea may be assigned to asthma without variable airflow evidence
Symptomatic people without a label Population case-finding identifies clinically important undiagnosed obstructive airway disease (Aaron 2018, PMID 29756989) Preventable symptoms, attacks and work loss
Children labeled from symptoms alone ERS notes frequent over- and under-diagnosis and rejects history-only diagnosis (Gaillard 2021, PMID 33863747) Both overtreatment and exposure to avoidable attack risk

An inability to confirm current asthma after treatment withdrawal does not prove the original episode never occurred; spontaneous remission and treatment suppression are alternative explanations. The clinically honest label is therefore “current asthma not demonstrated” unless records establish the original diagnosis (Aaron 2017, PMID 28114551).

Common discordances and what they imply

Pattern More likely explanations Next discriminating step
Symptoms, normal spirometry, negative bronchodilator test Intermittent asthma, treated asthma, inducible laryngeal obstruction, dysfunctional breathing, cardiac disease Repeat when symptomatic; challenge; inspect inspiratory loop; exercise/laryngoscopy as indicated
Fixed obstruction, weak reversibility Airway remodeling, COPD, bronchiectasis, bronchiolitis Smoking/exposure history, diffusion capacity, imaging and longitudinal variability; avoid defining overlap by spirometry alone (Rhee 2015, PMID 26161009)
High FeNO, little variability Atopy, eosinophilic bronchitis, treated asthma Confirm variable physiology; assess eosinophils, rhinitis and ICS exposure
Low FeNO, convincing variability Non-type-2 asthma, smoking effect, current ICS Do not exclude asthma; phenotype separately (Loewenthal 2022, PMID 35253144)
“Wheeze” over neck, abrupt onset/offset, inspiratory limitation Inducible laryngeal obstruction Laryngoscopy during symptoms or exercise; spirometry may be normal (He 2022, PMID 36097932)
Symptoms mainly at work, improve away Occupational asthma or work-exacerbated asthma Serial PEF at/on/off work, sensitization tests for appropriate agents, early specialist assessment (Jolly 2015, PMID 26461873)

Implementation gap

Barriers to objective testing in primary care include limited equipment and trained staff, time, uncertainty interpreting variable results, and therapeutic momentum after an empirical label. A systematic review mapped barriers at clinician, patient and system levels rather than identifying a single knowledge deficit (Yamada 2022, PMID 34740591).

Economic modeling found that objective diagnostic verification can be cost-effective by preventing unnecessary treatment and redirecting patients with alternative disease, but the result depends on test access, medication costs and the probability of misdiagnosis (Yaghoubi 2020, PMID 31837372).

The practical quality metric is not “spirometry once.” It is the proportion of long-term asthma labels supported by acceptable objective evidence or an explicitly documented reason why confirmation was not possible.

Open questions

  • What sequential test combination maximizes diagnostic yield per visit across different pre-test probabilities? Existing reviews establish imperfections but not one universal pathway (Armeftis 2023, PMID 37358228; Aaron 2018, PMID 29756989).
  • Can home spirometry or digital PEF produce trustworthy variability measures outside highly supported studies?
  • Which patients with a negative treated-state challenge can safely taper therapy for diagnostic reassessment? The Canadian algorithm was structured and supervised, not an invitation to unsupervised withdrawal (Aaron 2017, PMID 28114551).
  • How should oscillometry be integrated when symptoms suggest small-airway disease but spirometry is preserved? Peripheral-airway abnormalities can occur despite normal conventional spirometry (Malinovschi 2025, PMID 40371566).
  • Which implementation intervention closes the objective-testing gap in resource-constrained primary care? Known barriers span equipment, skill and workflow (Yamada 2022, PMID 34740591).

References

  1. Rothe T, et al. Diagnosis and management of asthma. Respiration. 2018. PMID 29614508
  2. Brigham EP, West NE. Diagnosis of asthma: diagnostic testing. Int Forum Allergy Rhinol. 2015;5 Suppl 1:S27-30. PMID 26335833
  3. Armeftis C, et al. An update on asthma diagnosis. J Clin Med. 2023;12. PMID 37358228
  4. Aaron SD, et al. Underdiagnosis and overdiagnosis of asthma. Am J Respir Crit Care Med. 2018;198:1012-1020. PMID 29756989
  5. Cockcroft DW. Methacholine challenge testing in the diagnosis of asthma. Chest. 2020. PMID 32768054
  6. Tepper RS, et al. Asthma outcomes: pulmonary physiology. J Allergy Clin Immunol. 2012;129:S65-87. PMID 22386510
  7. Urso DL. Diagnosis and treatment of asthma. Rev Bras Clin Med. 2012. PMID 22825384
  8. Boparai S, et al. Interpretation of spirometry, peak flow, and provocation testing for asthma. Med Clin North Am. 2024;108:1-16. PMID 38151386
  9. Dean BW, et al. Between-visit variability in FEV1 as a diagnostic test for asthma in adults. Eur Respir J. 2018;52. PMID 29877740
  10. Jolly AT, Klees JE, Pacheco KA, et al. Work-related asthma. J Occup Environ Med. 2015;57:e121-129. PMID 26461873
  11. Tarlo SM, et al. Laboratory challenge testing for occupational asthma. J Allergy Clin Immunol. 2003;111:692-694. PMID 12704344
  12. Selvanathan J, et al. Performance characteristics of spirometry with negative bronchodilator response and methacholine challenge testing and implications for asthma diagnosis. Chest. 2020;158:479-490. PMID 32298731
  13. Loewenthal L, Menzies-Gow A. FeNO in asthma. Semin Respir Crit Care Med. 2022;43:635-645. PMID 35253144
  14. Escamilla-Gil JM, et al. Understanding the cellular sources of fractional exhaled nitric oxide and its role as a biomarker of type 2 inflammation in asthma. Biomed Res Int. 2022;2022:5753524. PMID 35547356
  15. Dweik RA, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels for clinical applications. Am J Respir Crit Care Med. 2011;184:602-615. PMID 21885636
  16. Butler CA, et al. Fractional exhaled nitric oxide and asthma treatment adherence. Curr Opin Pulm Med. 2021;27:59-64. PMID 33369570
  17. Gaillard EA, et al. European Respiratory Society clinical practice guidelines for the diagnosis of asthma in children aged 5-16 years. Eur Respir J. 2021;58. PMID 33863747
  18. Chawes B, et al. Pulmonary function testing for the diagnosis of asthma in preschool children. Curr Opin Allergy Clin Immunol. 2022;22:101-110. PMID 35197431
  19. Danvers L, et al. The role of objective tests to support a diagnosis of asthma in children. Paediatr Respir Rev. 2020;34:52-57. PMID 30954449
  20. Aaron SD, et al. Reevaluation of diagnosis in adults with physician-diagnosed asthma. JAMA. 2017;317:269-279. PMID 28114551
  21. Aaron SD, et al. Overdiagnosis of asthma in obese and nonobese adults. CMAJ. 2008;179:1121-1131. PMID 19015563
  22. Rhee CK. Phenotype of asthma-chronic obstructive pulmonary disease overlap syndrome. Korean J Intern Med. 2015;30:443-449. PMID 26161009
  23. He LX, et al. Differential diagnosis of asthma and dysfunctional breathing and vocal cord dysfunction. Dtsch Med Wochenschr. 2022. PMID 36097932
  24. Yamada J, et al. Barriers and enablers to objective testing for asthma and COPD in primary care: a systematic review using the Theoretical Domains Framework. Chest. 2022;161:888-905. PMID 34740591
  25. Yaghoubi M, et al. Cost-effectiveness of implementing objective diagnostic verification of asthma in the United States. J Allergy Clin Immunol. 2020;145:1453-1461. PMID 31837372
  26. Malinovschi A, et al. Pulmonary function testing in asthma. Rev Mal Respir. 2025. PMID 40371566